Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of Buy by Analysts

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has earned a consensus rating of “Buy” from the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. Eleven investment analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have updated their coverage on the stock in […]

Related Keywords

United States ,Canada ,Mike Ouimette ,Eric Lefebvre ,Tekla Capital Management ,Virtu Financial ,Jpmorgan Chase Co ,Canaccord Genuity Group ,Pliant Therapeutics Inc ,Needham Company ,Royal Bank ,Securities Exchange Commission ,Fernwood Investment Management ,Nasdaq ,Pliant Therapeutics ,Get Free Report ,Marketbeat Ratings ,Genuity Group ,Therapeutics Stock Down ,Exchange Commission ,General Counsel Mike Ouimette ,Investment Management ,Capital Management ,Hill Capital Management ,Get Free ,Pliant Therapeutics Daily ,Nasdaq Plrx ,Plrx ,Medical ,Ratings ,Consensus ,